Literature DB >> 1196223

Bioavailability of phenytoin from various pharmaceutical preparations in children.

J I Manson, S M Beal, A Magarey, A C Pollard, W J O'Reilly, L N Sansom.   

Abstract

In children, the blood level of phenytoin was found to be significantly higher when 100 mg capsules rather than 100 mg tablets were administered. When, on the other hand, 30 mg capsules and tablets were compared; the situation was reversed; tablets produced significantly higher blood levels of phenytoin than did the capsules. The significance and possible explantation of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1196223     DOI: 10.5694/j.1326-5377.1975.tb106113.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  6 in total

Review 1.  Is generic prescribing acceptable in epilepsy?

Authors:  F M Besag
Journal:  Drug Saf       Date:  2000-09       Impact factor: 5.606

2.  Comparison of serum phenytoin levels in epileptic patients who swallowed their phenytoin tablets with or without previous chewing.

Authors:  P Bielmann; T Levac
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

3.  Bioavailability and dissolution of proprietary and generic formulations of phenytoin.

Authors:  I Soryal; A Richens
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-08       Impact factor: 10.154

4.  Impact of generic substitution of anticonvulsants on the treatment of epilepsy.

Authors:  A Richens
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

5.  Bioavailability of three phenytoin preparations in healthy subjects and in epileptics.

Authors:  B Rambeck; H E Boenigk; E Stenzel
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.